Mechanisms of minor histocompatibility antigen immunogenicity: The role of infinitesimal versus structurally profound polymorphisms

Immunologic Research

Volumn 36, Issue 1-3, 2006, Pages 33-41

  Brickner, Anthony G ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Antigen processing; Graft versus host disease; Graft versus leukemia effects; Minor histocompatibility antigens; Nonsense polymorphisms

Indexed keywords

MINOR HISTOCOMPATIBILITY ANTIGEN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AMINO ACID SEQUENCE; CELLULAR IMMUNITY; DNA POLYMORPHISM; DNA SEQUENCE; GENE TARGETING; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNOGENICITY; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

EID: 33947165393     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/ir:36:1:33     Document Type: Review

References (41)

1. Hinds DA, Stuve LL, Nilsen GB, et al: Whole-genome patterns of common DNA variation in three human populations. Science 2005;307:1072-1079.
2. Schwab SR, Li KC, Kang C, Shastri N: Constitutive display of cryptic translation products by MHC class I molecules. Science 2003;301:1367-1371.
3. Horowitz MM, Gale RP, Sondel PM, et al: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-562.
4. Barrett AJ, Van Rhee F: Graft-versus-leukaemia. Baillieres Clin Haematol 1997;10:337-355.
5. Weiden PL, Flournoy N, Thomas ED, et al: Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979;300:1068-1073.
6. Bleakley M, Riddell SR: Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer 2004;4:371-380.
7. Kolb HJ, Schattenberg A, Goldman JM, et al: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia 1. Blood 1995;86:2041-2050.
8. Slavin S, Naparstek E, Nagler A, Ackerstein A, Kapelushnik J, Or R: Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 1995;23:1553-1562.
9. Falkenburg JH, Willemze R: Minor histocompatibility antigens as targets of cellular immunotherapy in leukaemia. Best Pract Res Clin Haematol 2004;17:415-425.
10. Riddell SR, Bleakley M, Nishida T, Berger C, Warren EH: Adoptive transfer of allogeneic antigen-specific T cells. Biol Blood Marrow Transplant 2006;12:9-12.
11. Ferrara JL, Deeg HJ: Graft-versus-host disease. N Engl J Med 1991;324:667-674.
12. Chao NJ: Minors come of age: Minor histocompatibility antigens and graft-versus-host disease. Biol Blood Marrow Transplant 2004;10:215-223.
13. de Bueger M, Bakker A, van Rood JJ, Van der WF, Goulmy E: Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J Immunol 1992;149:1788-1794.
14. Warren EH, Greenberg PD, Riddell SR: Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood 1998;91:2197-2207.
15. den Haan JM, Sherman NE, Blokland E, et al: Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 1995;268:1476-1480.
16. den Haan JM, Meadows LM, Wang W, et al: The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science 1998;279:1054-1057.
17. Dolstra H, Fredrix H, Maas F, et al: A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia. J Exp Med 1999;189:301-308.
18. de Rijke B, van Horssen-Zoetbrood A, Beekman JM, et al: A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia. J Clin Invest 2005;115:3506-3516.
19. Warren EH, Gavin MA, Simpson E, et al: The human UTY gene encodes a novel HLA-B8-restricted H-Y antigen. J Immunol 2000;164:2807-2814.
20. Brickner AG, Evans AM, Mito JK, et al: The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL. Blood 2006;107:3779-3786.
21. Akatsuka Y, Nishida T, Kondo E, et al: Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens. J Exp Med 2003;197:1489-1500.
22. Goulmy E: Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol Rev 1997;157:125-140.
23. Simpson E, Roopenian D: Minor histocompatibility antigens. Curr Opin Immunol 1997;9:655-661.
24. Mendoza LM, Paz P, Zuberi A, Christianson G, Roopenian D, Shastri N: Minors held by majors: the H13 minor histocompatibility locus defined as a peptide/MHC class I complex. Immunity 1997;7:461-472.
25. McBride K, Baron C, Picard S, et al: The model B6(dom1) minor histocompatibility antigen is encoded by a mouse homolog of the yeast STT3 gene. Immunogenet 2002;54:562-569.
26. Dolstra H, Rijke BB, Fredrix H, et al: Bi-directional allelic recognition of the human minor histocompatibility antigen HB-1 by cytotoxic T lymphocytes. Eur J Immunol 2002;32:2748-2758.
27. Yadav R, Yoshimura Y, Boesteanu A, et al: The H4b minor histocompatibility antigen is caused by a combination of genetically determined and posttranslational modifications. J Immunol 2003;170:5133-5142.
28. Roopenian D, Choi EY, Brown A: The immunogenomics of minor histocompatibility antigens. Immunol Rev 2002;190:86-94.
29. Engelhard VH, Brickner AG, Zarling AL: Insights into antigen processing gained by direct analysis of the naturally processed class I MHC associated peptide repertoire. Mol Immunol 2002;39:127-137.
30. Malarkannan S, Horng T, Eden P, et al: Differences that matter: major cytotoxic T cell-stimulating minor histocompatibility antigens. Immunity 2000;13:333-344.
31. Murata M, Warren EH, Riddell SR: A human minor histocompatibility antigen resulting from differential expression due to a gene deletion. J Exp Med 2003;197:1279-1289.
32. Spierings E, Brickner AG, Caldwell JA, et al: The minor histocompatibility antigen HA-3 arises from differential proteasome-mediated cleavage of the lymphoid blast crisis (Lbc) oncoprotein. Blood 2003;102:621-629.
33. Brickner AG, Warren EH, Caldwell JA, et al: The immunogenicity of a new human minor histocompatibility antigen results from differential antigen processing. J Exp Med 2001;193:195-206.
34. b epitope is encoded by a novel mouse Y chromosome gene. Nat Genet 1996;14:474-478.
35. Mommaas B, Kamp J, Drijfhout JW, et al: Identification of a novel HLA-B60-restricted T cell epitope of the minor histocompatibility antigen HA-1 locus. J Immunol 2002;169:3131-3136.
36. Schuler MM, Donnes P, Nastke MD, Kohlbacher O, Rammensee HG, Stevanovic S: SNEP: SNP-derived epitope prediction program for minor H antigens. Immunogenet 2005;57:816-820.
37. Cresswell P: Cell biology. Cutting and pasting antigenic peptides. Science 2004;304:525-527.
38. Shastri N, Schwab S, Serwold T: Producing nature's gene-chips: the generation of peptides for display by MHC class I molecules. Annu Rev Immunol 2002;20:463-493.
39. Mendell JT, Dietz HC: When the message goes awry: disease-producing mutations that influence mRNA content and performance. Cell 2001;107:411-414.
40. Weber JL, David D, Heil J, Fan Y, Zhao C, Marth G: Human diallelic insertion/deletion polymorphisms. Am J Hum Genet 2002;71:854-862.
41. Warren EH, Otterud BE, Linterman RW, et al: Feasibility of using genetic linkage analysis to identify the genes encoding T cell-defined minor histocompatibility antigens. Tissue Antigens 2002;59:293-303.